Recent Pfizer Press Releases

10/7/15 7:00am EDT
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma

  • Fast Track milestone for avelumab builds upon recent Orphan Drug designation in this aggressive skin cancer
  • Fast Track designation highlights the serious, unmet medical need that exists for patients with this disease

Merck KGaA, Darmstadt, Germany, and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.

10/2/15 9:04am EDT
Pfizer Inc. Announces Final Results of Exchange Offers

Pfizer Inc. (“Pfizer”) (NYSE: PFE) announced today the final results of its previously announced offers to exchange any and all validly tendered and accepted notes of each series listed in the table below (collectively, the “Hospira Notes”) issued by Hospira, Inc., a recently acquired subsidiary of Pfizer, for new notes to be issued by Pfizer (collectively, the “Pfizer Notes”), and the related solicitations of consents to amend the indenture governing the Hospira Notes and the Hospira Notes (together, the “Exchange Offers”). A Registration Statement on Form S-4 (File No. 333-206758) (the “Registration Statement”) relating to the issuance of the Pfizer Notes was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2015, was amended by Amendment No. 1 to the Registration Statement filed with the SEC on September 16, 2015, and was declared effective by the SEC on September 25, 2015.

10/1/15 8:00am EDT
Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline

Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.

9/30/15 5:00pm EDT
Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers

Next chapter of the “Breast Cancer: A Story Half Told” initiative encourages all to share photos and messages of hope using the hashtag #StoryHalfTold

Pfizer Inc., in partnership with five leading breast cancer advocacy organizations, today announced the next chapter of the Breast Cancer: A Story Half Told initiative, launched in 2014 to identify public misperceptions and gaps in knowledge surrounding metastatic breast cancer (MBC), the most advanced form of breast cancer. 

9/30/15 8:30am EDT
Pfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results From September 3, 2015 Through Year-End 2015

  • Raises 2015 Financial Guidance(1) Ranges for Reported Revenues(2) by $1.5 Billion and Adjusted Diluted EPS(3) by $0.03 Solely Due to the Inclusion of Legacy Hospira Operations in Pfizer's Financial Results
  • Lowers 2015 Financial Guidance(1) Range for Reported Diluted EPS(2) by $0.09 Reflecting Inclusion of Legacy Hospira Operations More than Offset by Anticipated Negative Impacts of Associated Purchase Accounting Adjustments as well as Restructuring and Other Acquisition-Related Costs

Pfizer Inc.

9/30/15 8:00am EDT
Is 50 Really the New 30? Your Immune System May Not Think So

Actor Tim Daly in partnership with the American Lung Association and Pfizer launches the WHO PNEU?™ Campaign – Urging adults 50 and older to know their Pneumococcal pneumonia risk

The American Lung Association in partnership with Pfizer announces the launch ofWHO PNEU?™, a public awareness campaign encouraging Baby Boomers and older Gen X-ers to recognize their personal risk for pneumococcal pneumonia — a serious lung disease1 that can be spread by coughing and sneezing.2 

9/24/15 12:01am EDT
Pfizer’s Sayana® Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection

Builds on Current Momentum Towards Broadening Access to This Contraceptive Option for Women Across the Globe

Pfizer Inc. announced today that the company’s injectable contraceptive, Sayana®Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection. 

9/22/15 10:00am EDT
New Centrum® VitaMints® Offer a Refreshingly New Way to Take a Multivitamin

America’s Most-Preferred Multivitamin Brand Now Available in Cool Mint Flavor for Consumers to Enjoy Like a Mint

The refreshing flavor of mint is a pleasurable enhancement to toothpastes, chewing gums, culinary fare – and now, America’s most-preferred multivitamin brand.

9/21/15 8:00am EDT
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Oral Tofacitinib in Adults with Moderate-to-Severe Ulcerative Colitis

Pfizer Inc. announced today top-line results from two Phase 3 induction trials of tofacitinib 10 mg twice daily (BID) tablets in the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) global clinical development program for the treatment of adults with moderate to severe ulcerative colitis (UC): OCTAVE Induction 1 (A3921094) and OCTAVE Induction 2 (A3921095). 

9/16/15 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 27, 2015. 

9/11/15 4:00am EDT
Merck KGaA, Darmstadt, Germany and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015

  • Data from six abstracts, including new data in mesothelioma, urothelial, (e.g. bladder) and gastric/gastroesophageal cancers, to be presented at the European Cancer Congress (ECC)
  • Additional findings for non-small cell lung cancer (NSCLC) and ovarian cancers build on previously presented data

Merck KGaA, Darmstadt, Germany and Pfizer today announced that six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab* will be presented at this year’s ECC in Vienna, Austria, September 25–29, 2015.

9/3/15 5:17pm EDT
Pfizer Inc. Commences Exchange Offers for Hospira Notes

Pfizer Inc. ("Pfizer") (NYSE:PFE) announced today that it has commenced offers to exchange any and all validly tendered and accepted notes of the following series issued by Hospira, Inc. ("Hospira"), our recently acquired subsidiary, for new notes to be issued by Pfizer as described in the table below.

9/3/15 9:00am EDT
Pfizer Completes Acquisition of Hospira

  • Creates a leading Global Established Pharmaceutical (GEP) Business
  • Expected to be immediately accretive to adjusted diluted EPS  upon closing; $0.10-$0.12 accretion to adjusted diluted EPS expected in first full year after close with additional accretion anticipated thereafter

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Hospira, Inc.

8/26/15 7:30am EDT
Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer

Partnership with Pfizer, BIG, GBG, NSABP and PrECOG to facilitate further investigation of IBRANCE

The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib Collaborative AdjuvantStudy, or PALLAS.

8/24/15 8:15am EDT
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015

  • Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates and healthcare costs among patients with nonvalulvar atrial fibrillation (NVAF) receiving novel oral anticoagulant (NOACs)
  • Results from the AEGEAN (Assessment of an Educational and Guidance Programme for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study will also be presented as a late-breaking trial

8/24/15 8:00am EDT
Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition

  • FTC Consent Order includes agreement to divest four sterile injectable assets
  • Brazil’s Superintendency-General of the Council for Economic Defense (CADE) has published its unconditional clearance decision
  • Transaction expected to close in early September 2015

Pfizer Inc. today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Hospira. 

8/21/15 8:00am EDT
Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA® (Meningococcal Group B Vaccine)

Data Consistent with Immunogenicity and Safety Data from Previous Studies

Pfizer Inc. (NYSE:PFE) announced today positive topline results of two Phase 3 studies of TRUMENBA® (Meningococcal Group B Vaccine). 

8/20/15 11:23am EDT
Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer

Pfizer Inc. today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for IBRANCE® (palbociclib) in combination with endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.